Home » GE Healthcare Acquires Wave Biotech LLC
GE Healthcare Acquires Wave Biotech LLC
PharmaManufacturing.com
04/16/2007
Wave Biotech develops and manufactures unique bioreactors which are designed to replace traditional and more expensive stainless steel tanks and piping. The patented products offer considerable advantages such as more rapid installation, potentially reducing time to market, and significantly lower costs by eliminating the need for cleaning and validating between batches. The equipment is already in use in over 300 companies worldwide. Wave Biotech's single-use bioreactors are also increasingly being used to enable the manufacture of patient-specific cell and gene therapy products.
Ann O’Hara, general manager of GE Healthcare’s BioProcess business, said, “Wave Biotech is an excellent company with a strong track record of innovation and a product range that is highly complementary with our existing BioProcess business. The combination of GE Healthcare and Wave Biotech will allow us to expand into new applications and to create a broad offering of added value tools and services for biopharmaceutical manufacture.”
"We are very excited to be part of GE Healthcare, who already offer a broad range of technologies and services to the biopharmaceutical manufacturing industry” said Dr. Vijay Singh, president and founder of Wave Biotech. "Our customers will benefit greatly from the global presence and the R&D resources that GE Healthcare brings to the table. The integration of single-use cell culture with GE Healthcare’s existing filtration and downstream operations will provide a host of new disposable solutions to this growing industry."
More News:
- 03/18/2010 Teva Beats Out Pfizer & Activa in 3.5BN Rationpharm Generics DealFrom CTV.ca
- 03/18/2010 Johnson & Johnson CEO Weldon Gets 11% 2009 Raise, to $25.6MFrom AP.com
- 03/17/2010 $75 Million Drug Heist is Bitter Pill for LillyFrom IndyStar.com
- 03/17/2010 R&D Investment by U.S. Biopharmaceutical Companies Remains Strong Despite Ongoing Economic Challenges
- 03/15/2010 Diabetes Drug From Lilly, Amylin Under ScrutinyFrom Forbes.com
- 03/12/2010 AstraZeneca Inks First Generic Drugs DealFrom Business.timesonline.co.uk
- 03/12/2010 AstraZeneca Job Cuts Reflect New Landscape For Drug InnovationFrom FT.com
- 03/10/2010 Novartis Goes Wireless for Process and Plant Info
- 03/10/2010 Concerns Raised about Tromethamine ContaminationFrom Rx-360
- 03/09/2010 Pittcon 2010: Thermo Fisher Scientific Continues in Growth Mode
- All news »
More content on this topic:
Get Connected Now!
- Featured White Papers

Print page